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The first study relating external beam radiation exposure during
childhood and thyroid tumorigenesis was described in 1950
(Duffy and Fitzgerald, 1950). Since then, an increased incidence
of thyroid cancers has been observed in several populations
including atomic bomb survivors (Conrad et al, 1970), patients
with a history of external radiation for benign or malignant condi-
tions (Shore et al, 1985), and more recently in children from
Belarus and Ukraine after the Chernobyl nuclear power plant
explosion (Kazakov et al, 1992). However, little is known
concerning the molecular mechanisms originating the radiation-
associated thyroid tumours. Radiation is able to induce DNA
strand breaks and deletions and stimulates aberrant recombination
events, giving rise to chromosomal translocations and intra-
chromosomal rearrangements (Roth et al, 1995). In ‘spontaneous’
papillary thyroid carcinomas, two proto-oncogenes, RET and
NTRK1, which encode membrane tyrosine kinase receptors, were
found activated by rearrangement with a variable frequency
(Bongarzone et al, 1996). Recently, we and others have reported a
high prevalence of RET rearrangements in thyroid tumours from
patients who had received therapeutic or accidental radiation (Ito
et al, 1994; Fugazzola et al, 1995; Klugbauer et al,1995; Bounacer
et al, 1997; Nikiforov et al, 1997). These data suggested that radi-
ation exposure may be, with a high frequency (more than 60%), a
direct inducer of RET rearrangements. Studies concerning the
research of alterations of other genes in radiation-associated
thyroid tumours are also available for ras, gsp and p53 (Wright et
al, 1991; Challeton et al, 1995; Fogelfeld et al, 1996; Nikiforov et
al, 1996). For NTRK1, there is only a recent study by Beimfohr et
al (1999) concerning exclusively post-Chernobyl tumours.
The human NTRK1 proto-oncogene (also called TRKA) is
located on the q arm of chromosome 1 (Weier et al, 1995) and
encodes one of the receptors of the nerve growth factor (NGF)
(Kaplan et al, 1991; Klein et al, 1991). NTRK1 gene transcripts
have been detected exclusively in peripheral nervous ganglia, indi-
cating that the gene plays a role in the nervous system develop-
ment and function (Martin-Zanca et al, 1990). NTRK1 was
originally detected as an oncogene (named TRK) in a human colon
carcinoma, following transfection of tumoural high molecular
weight DNA in NIH 3T3 cells and focus formation (Martin-Zanca
et al, 1986). This activated version of the proto-oncogene was
generated by a somatic intrachromosomal rearrangement fusing
the tyrosine kinase (TK) domain of NTRK1 with 5¢ sequences of
the non-muscular tropomyosin gene (TPM3). NTRK1 proto-onco-
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Summary Rearrangements of NTRK1 proto-oncogene were detected in ‘spontaneous’ papillary thyroid carcinomas with a frequency
varying from 5 to 25% in different studies. These rearrangements result in the formation of chimaeric genes composed of the tyrosine kinase
domain of NTRK1 fused to 5¢ sequences of different genes. To investigate if the NTRK1 gene plays a role in radiation-induced thyroid
carcinogenesis, we looked for the presence of NTRK1-activating rearrangements in 32 human thyroid tumours (16 follicular adenomas, 14
papillary carcinomas and two lymph-node metastases of papillary thyroid carcinomas) from patients who had received external radiation,
using the reverse transcription polymerase chain reaction, Southern blot and direct sequencing techniques. These data were compared with
those obtained in a series of 28 ‘spontaneous’ benign and malignant thyroid tumours, collected from patients without a history of radiation
exposure and four in vitro culture cell lines derived from ‘spontaneous’ thyroid cancers. Our results concerning the radiation-associated
tumours showed that only rearrangements between NTRK1 and TPM3 genes (TRK oncogene) were detected in 2/14 papillary carcinomas
and in one lymph-node metastasis of one of these papillary thyroid carcinomas. All the radiation-associated adenomas were negative. In the
‘spontaneous’ tumours, only one of the 14 papillary carcinomas and one of the four in vitro culture cell lines, derived from a papillary
carcinoma, presented a NTRK1 rearrangement also with the TPM3 gene. Twenty-five of this series of radiation-associated tumours were
previously studied for the ras and RET/PTC oncogenes. In conclusion, our data: (a) show that the overall frequency of NTRK1
rearrangements is similar between radiation-associated (2/31: 6%) and ‘spontaneous’ epithelial thyroid tumours (2/32: 6%). The frequency, if
we consider exclusively the papillary carcinomas, is in both cases 12%; (b) show that the TRK oncogene plays a role in the development of a
minority of radiation-associated papillary thyroid carcinomas but not in adenomas; and (c) confirm that RET/PTC rearrangements are the
major genetic alteration associated with ionizing radiation-induced thyroid tumorigenesis. © 2000 Cancer Research Campaign
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Correspondence to: HG Suárezgene rearrangements have been described also in human papillary
thyroid carcinomas (PTC). In these tumours, the NTRK1 onco-
genic rearrangements are the consequence of the fusion of the TK
domain of NTRK1 with at least three different genes: the TPM3
gene as found in the original TRK oncogene (Butti et al, 1995); the
TPR (translocated promoter region) gene, also located on chromo-
some 1q and first identified as part of the MET oncogene (TPR-
MET) (Park et al, 1986), giving rise at two different oncogenes:
TRK-T1 and TRK-T2 (Greco et al, 1992); and the TFG (TRK-fused
gene) gene which function is unknown and located on chromo-
some 3, originating the TRK-T3 oncogene (Greco et al, 1995). All
these oncogenic forms of NTRK1 encode cytoplasmic chimaeric
proteins which are constitutively phosphorylated on tyrosine. The
frequency of NTRK1 activation in ‘spontaneous’ thyroid tumours
(exclusively in PTC) varies from 15 to 25% in tumours from
Italian patients (Bongarzone et al, 1989; Greco et al, 1992; Butti et
al, 1995) to less than 5% in French and Japanese studies
(Wajjwalku et al, 1992; Said et al, 1994; Delvincourt et al, 1996).
To determine if the NTRK1 proto-oncogene activating
rearrangements play a role in thyroid radiation-induced carcino-
genesis, we studied a series of benign and malignant human
thyroid tumours which were obtained from patients who had
received external radiation therapy. We compared these data with
those obtained by us: (1) in a series of ‘spontaneous’ thyroid
tumours, collected from patients without any history of radiation
exposure and (2) with that previously obtained (Challeton et al,
1995; Bounacer et al, 1997) after the study of 25 of the radiation-
associated tumours, looking for the presence of activated ras and
Ret genes.
MATERIALS AND METHODS
Patients
Tumours were collected at the Gustave Roussy Institute (Villejuif,
France) and were histologically classified according to the WHO
recommendations (Hedinger et al, 1989). A total of 31 tumours
obtained from patients with a history of external irradiation for
benign or malignant conditions, were examined: 16 follicular
adenomas, 14 PTC and two lymph-node metastases of PTC
(LNMPTC) including one from a patient whose primary thyroid
tumour was also studied (Table 1). The doses received by the
thyroid have been calculated according to Diallo et al (1996), for
23/31 of our patients treated for their first benign or malignant
condition in the Gustave Roussy Institute. As controls, we studied
28 ‘spontaneous’ human thyroid tumours, collected from patients
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Table 1 TRK rearrangements in thyroid tumours from patients exposed to ionizing radiation
Age at irradiation (yr) Age at tumour TRK rearrangement
Patient Sex and dose (Gy)a Cause diagnosis (yr) Histologyb research by RT-PCR
PE1d e Female 1/4.5 Haemangioma 20 PTC –
JE2e Male 26/14 Hodgkin’s disease 36 PTC +
JE3e Male 26/14 Hodgkin’s disease 36 LNMPTC +
AU4e Female 3/ndc Bronchial cyst 38 PTC –
MA5e Female 2/nd Neck furuncle 22 PTC –
GO6e Male 10/1.4 Parotid tumour 18 PTC –
VA7e Female 28/nd Neck zona 50 PTC –
DZ8e Female 7/2 Neck tuberc. 38 PTC –
SO9e Female 23/0.03 Tonsil 46 PTC –
TS10e Male 23/11 Hodgkin’s disease 36 PTC –
AM11 Male 13/21 Goitre 57 PTC –
DE12 Female 32/16 Breast carcinoma 55 PTC –
PA13e Female 1/nd Cutaneous angioma 36 LNMPTC –
BO14 Male 26/nd Zona upper limb 33 PTC +
FO15e Female 5/0.001 Benign rum 33 PTC –
FA16 Male 8/23 Goitre 30 PTC –
PL17d e Female 12/nd Acne 42 Macr. Ad. –
SA18e Male 25/nd Tonsil 53 Micr. Ad. –
BO19e Female 10/12.5 Hodgkin’s disease 30 Mix. Ad. –
PE20e Female 26/12 Hodgkin’s disease 46 Micr. Ad. –
AK21 Female 23/11.5 Lymphoma 33 Micr. Ad. –
LA22d Female 4/15.5 Hodgkin’s disease 18 Mix. Ad. –
RE23 Female 12/10.5 Hodgkin’s disease 38 Mix. Ad. –
MA24e Male 13/13 Hodgkin’s disease 34 Micr. Ad. –
AB25 Female 5/7.3 Nephroblastoma 25 Micr. Ad. –
OF26e Male 4/29.2 Medulloblastoma 21 Micr. Ad. –
CA27e Female 5/27.6 Neuroblastoma 29 Macr. Ad. –
JA28 Male 3/nd Neck tuberc. 39 Micr. Ad. –
RO29e Male 1/10 Neuroblastoma 27 Micr. Ad. –
PA30 Male 6/14 Hodgkin’s disease 21 Macr. Ad. –
FA31 Female 27/10.5 Hodgkin’s disease 34 Mix. Ad. –
AU32e Female 29/11.5 Hodgkin’s disease 47 Macr. Ad. –
aDose received by the thyroid calculated according to Diallo et al. (1996). bPTC: papillary thyroid carcinoma; LNMPTC: lymph-node metastasis of
papillary thyroid carcinoma; Macr. Ad.: macrofollicular adenoma.; Micr. Ad.: microfollicular adenoma; Mix. Ad.: mixed adenoma (samples from
tumours with both macro- and microfollicular features). cnd: not done. dSamples positive for ras (Challeton et al, 1995). eSamples positive for
RET/PTC (Bounacer et al, 1997 and this study).without any history of radiation: 14 follicular adenomas and 14
PTC (Table 2). Four in vitro cultured human cell lines, three (K2,
K5 and K8) derived from ‘spontaneous’ PTC and one (K7) from a
follicular less-differentiated carcinoma (Challeton et al, 1997),
were also screened.
The genetic material used in our study was extracted from
frozen tissues of radiation-associated tumours (Table 1) in the case
of patients MA5, PA13, PE20 and CA27; for all the other samples
the tissues used were paraffin-embedded. Concerning ‘sponta-
neous’ tumours (Table 2), the genetic material was extracted in all
the cases from frozen tissues, with the exception of CO1, CH4,
FR7, SZ9, AL11, KR12, MA13, TA14, AM27 and FA28 for which
the tissues were paraffin-embedded (Table 2).
RNA extraction
RNA isolation from Duboss or Bouin fixed paraffin-embedded
tissue samples, was performed according to a previously described
procedure (Bounacer et al, 1997). Total RNA was extracted from
frozen tissues, using the RNA-BTM technique (Bioprobe Systems,
France) following the manufacturer’s instructions. Total RNA was
extracted from in vitro culture cells as described by Michelin et al
(1993). The quality of the RNAs was controlled by reverse tran-
scription polymerase chain reaction (RT-PCR) amplification using
b-actin specific primers as described by Viglietto et al (1995).
RT-PCR method for detecting TRK oncogenes
The reverse transcription reaction was performed as previously
described (Bounacer et al, 1997) using half the volume of RNA
extracted from paraffin-embedded tissue extracts or 1.5 mg of total
RNA from fresh tissue extracts. One fourth of the cDNA was used
for PCR amplification with outer primers. For the paraffin-
embedded tissue extracts, a second round of PCR was done with
nested primers using 1:10 of the first round PCR product. The
PCR amplifications were performed as previously described
(Bounacer et al, 1997), using an automatic thermocycler
(GeneAmp, Perkin-Elmer, France). Ten ml of PCR product were
electrophoresed in a 2% agarose gel. PCR primer sequences used
in this study are given in Table 3.
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Table 2 TRK rearrangements in human ‘spontaneous’ thyroid tumours (A) and in vitro culture cell lines (B)
A
TRK rearrangement research by
Age at
Patient Sex tumour Histologya RT-PCR Southern blot
diagnosis (years)
CO1d Female 37 PTC – NDb
SE2c d Female 15 PTC – –
QU3 Male 39 PTC – –
CH4d Female 32 PTC ND –
SE5 Male 75 PTC – –
MA6 Female 46 PTC – –
FR7 Female 27 PTC ND –
BL8d Female 44 PTC – –
SZ9 Female 39 PTC ND +
UR10 Male 55 PTC – –
AL11c Male 36 PTC ND –
KR12 Female 13 PTC – ND
MA13 Male 57 PTC ND –
TA14 Female 30 PTC ND –
DU15c Female 56 Macr. Ad. – –
CO16c Female 22 Macr. Ad. – –
RO17 Female 28 Mix. Ad. – –
FA18 Female 43 Micr. Ad. – –
CO19 Female 50 Macr. Ad. – –
GH20c Female 37 Macr. Ad. – –
ME21 Female 42 Macr. Ad. – –
DE22 Female 29 Micr. Ad. – –
GU23c Female 46 Mix. Ad. – –
RE24 Male 69 Mix. Ad. – –
SA25 Female 64 Macr. Ad. – –
TH26c Female 37 Mix. Ad. – –
AM27 Female 35 Macr. Ad. ND –
FA28 Female 43 Mix. Ad. ND –
B
Cell lines Derived from TRK rearrangement
research by RT-PCR
K2 PTC –
K5 PTC +
K7 FLDCe –
K8 PTC –
a Abreviations are the same as in Table 1. b ND: not done. c Samples positive for ras (Said et al, 1994). d Samples positive for
RET/PTC (Bounacer et al, 1997). e Follicular less-differentiated carcinoma.DNA extraction and Southern blot analysis
Genomic DNA was extracted from the frozen tissues as described
by Suárez et al (1990, 1991). Southern blot analysis was
performed as previously described (Delvincourt et al, 1996) using
as probes, a 1.2 kb BalI-EcoRI fragment of pDM10-1 plasmid and
a 2.7 kb KpnI insert of pDM8 plasmid, specific respectively, for
the tyrosine kinase domain of the NTRK1 proto-oncogene and the
tropomyosin sequences (Martin-Zanca et al, 1986). Both plasmids
were kindly provided by Dr Martin-Zanca (Universidad de
Salamanca, Spain).
DNA sequence analysis
Direct sequencing of the amplified DNA fragments was carried
out by the dideoxy-nucleotide method (Sanger et al, 1977) with 33P
ATP, using the double strand DNA cycle sequencing system kit
(Gibco-BRL, Life Technologies, France) and the same primers as
those used in the amplification, following the manufacturer’s
conditions.
RESULTS
Presence of trk rearrangements in radiation-associated
and ‘spontaneous’ human thyroid tumours
A total of 31 radiation-associated thyroid tumours (16 follicular
adenomas, 14 PTC and two LNMPTC) (Table 1), were screened
for the presence of TRK, TRK-T1, TRK-T2 and TRK-T3 chimaeric
transcripts, using RT-PCR. As shown in Table 1, the majority of
our patients (20/31) were irradiated at a young age (less than 14
years old) and the dose received at the thyroid gland varied from
less than 1 to 29 Gy. TRK (TPM3-NTRK1) chimaeric transcripts
were only detected in 2/14 PTC. In patient JE, the TRK rearrange-
ment has been detected in both the primary tumour (JE2) and 
a lymph nodal metastasis (JE3) (Table 1). All the radiation-
associated follicular adenomas were negative. Figure 1A illus-
trates results of positive tumours. The quality of the extracted
RNAs is shown in Figure 1B. The TRK bands (254 bp) were
observed only after a second round of PCR, probably reflecting the
fact that these RNAs were prepared from a small volume of Bouin
or Duboss fixed sample. The three positive cases studied by RT-
PCR (including the LNMPTC of patient JE2) were confirmed by
sequencing the cDNA and one example of these sequences is
shown in Figure 2.
As controls, we studied 28 ‘spontaneous’ human thyroid
tumours, collected from patients without any history of radiation:
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Table 3 Sequences of the primers used in our experiments for RT-PCR
Primer sequences Nucleotide positionsa
NTRK1 primers:
TRK-F (forward) 5¢-TCAACAACGGCAACTACACG-3¢ 1145–1164
TRK-R2 (outer reverse) 5¢-CTTGATGTGGTGAACACAGG-3¢ 1632–1651
TRK-IR (in-nested reverse) 5¢-AACTTGTTTCTCCGTCCAC-3¢ 1565–1584
TPM3 primers:
TPM-F2 (outer forward) 5¢-TGAGCAGATTAGACTGATGG-3¢ 474–493
TPM-is (in-nested forward) 5¢-TGATAAACTCAAGGAGGCAG-3¢ 579–598
TPR primers:
TPR-F2 (outer forward) 5¢-AGAACCAATGAGAGACTATC-3¢ 399–418
TPR-is (in-nested forward) 5¢-GGATGAACTTCAAGCTTCTG-3¢ 512–531
TFG primers:
TFG-es2 (outer forward) 5¢-TGATACTGTGGATGGTAGGG-3¢ 431–450
TFG-F2 (in-nested forward) 5¢-AACAGTCTACTCAGGTTAT-3¢ 482–500
aNucleotide positions of the primers are based on the published sequences of NTRK1 (Martin-Zanca et al, 1989), TRK (Martin-
Zanca et al, 1986), TRK-T1 (Greco et al, 1992) and TRK-T3 cDNA (Greco et al, 1995).
872 bp
310 bp
118 bp
M123456
123456
b-actin
A
B
Figure 1 Detection by RT-PCR of NTRK1 rearrangements in the RNA of
radiation-associated and ‘spontaneous’ human thyroid tumours. (A) Ethidium
bromide-stained 2% agarose gel of second PCR round products. Lane 2:
NTRK1 expression in a ‘spontaneous’ tumour presenting a C-cell hyperplasia
(positive control); lanes 3 and 4: TRK oncogene in the radiation-associated
PTC of patient JE and its lymph-node metastasis respectively; lane 5: TRK
oncogene in the radiation-associated PTC from patient BO14; lane 6: TRK
oncogene in the cell line K5 derived from a human ‘spontaneous’ PTC. The
predicted sizes of second PCR round fragments for NTRK1 proto-oncogene
and TRK oncogene are 265 bp and 254 bp respectively. Lane 1 shows the
PCR amplification of RNA from a positive sample, which was not reverse
transcribed prior to PCR amplification (negative control). M: Molecular weight
marker ØX174/HaeIII. (B) The same RNAs in (A) were subjected to RT-PCR
amplification using b-actin specific primers which generate an 82 bp PCR
product. The products of the amplification were run on a 2% agarose gel and
ethidium bromide staining of the gel is presented14 follicular adenomas and 14 PTC (Table 2). Four in vitro
cultured human cell lines, three (K2, K5 and K8) derived from
‘spontaneous’ PTC and one (K7) from a follicular less-differenti-
ated carcinoma, were also screened. The presence of oncogenic
TRK, TRK-T1, TRK-T2 or TRK-T3 rearrangements was investi-
gated using the Southern blot and/or RT-PCR techniques (Table 2).
Only one papillary carcinoma (patient SZ9) was found positive for
TRK oncogene by Southern blot, using as probes a 1.2 kb BalI-
EcoRI fragment of pDM10-1 plasmid and a 2.7 kb KpnI insert of
pDM8 plasmid, specific respectively, for the tyrosine kinase
domain of the NTRK1 proto-oncogene and the tropomyosin
sequences (Martin-Zancaet al, 1986) (Figure 3 A, B). All the
‘spontaneous’ follicular adenomas were negative. One of the four
in vitro culture cell lines (K5) also presented a TRK rearrangement
(TPM3-NTRK1), as shown by RT-PCR (Figure 1A) and cDNA
sequence (data not shown).
Our results show that the overall frequency of NTRK1
rearrangements is similar in radiation-associated and ‘sponta-
neous’ thyroid tumours (6%). When the PTC are considered sepa-
rately, the frequencies are respectively 14% (2/14) and 12% (2/17)
in the radiation-associated and ‘spontaneous’ tumours.
Combined study of the ras, RET/PTC and TRK
oncogenes in radiation-associated tumours
Twenty-five of the radiation-associated tumours have been also
previously screened for the presence of ras mutations and
RET/PTC rearrangements (Challeton et al, 1995; Bounacer et al,
1997) (Table 1). Three samples were positive for ras, 15 for
RET/PTC and 2 for TRK (Table 1). The overall frequencies of ras,
RET and NTRK1 alterations in these radiation associated tumours
are 12%, 60% and 8% respectively. Two of the radiation-associ-
ated tumours (patients PE1 and PL17) presented simultaneously a
Ha-ras mutation and a RET/PTC1 rearrangement (Table 1). In the
remaining seven tumours which were not screened for ras (patient
JE and patients numbered from 11 to 16), we looked by RT-PCR,
for the presence of RET/PTC rearrangements. Three of these
tumours [one PTC (FO15) and two LNMPTC (JE3 and PA13)]
presented a RET/PTC1 rearrangement (data not shown).
Interestingly, one of them (JE2), presented simultaneously a
RET/PTC1 and a TRK rearrangement in both the primary tumour
and its lymph-nodal metastasis (Table 1).
DISCUSSION
In order to determine whether the NTRK1 gene plays a role in
radiation-associated thyroid tumorigenesis, we have studied 30
malignant and benign thyroid tumours and two lymph-node metas-
tases, collected at the Gustave Roussy Institute (Villejuif, France)
from patients with a history of external radiation (predominantly
in childhood) for benign or malignant conditions. The results
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Figure 2 Sequence analysis of RT-PCR cDNA prepared from TRK-positive
radiation-associated tumour from patient JE2. The fusion point of the TPM3
and NTRK1 genes is indicated by an arrow
12 3 4
23.1 kb
9.4 kb
6.7 kb
4.3 kb
AB
Figure 3 Southern blot analysis of the NTRK1 gene in: normal thyroid
tissue (lanes 1 and 4) and ‘spontaneous’ PTC from patient SZ9 (lanes 2 and
3). The DNAs (20 mg) were digested with (A) BamHI and hybridized with a
probe derived from the tyrosine kinase domain of NTRK1 (1.2 Kb Bal I-EcoRI
fragment of pDM10-1 plasmid) and (B) with EcoRI and hybridized with a
tropomyosin specific probe (2.7 Kb KpnI insert of pDM8 plasmid). Co-
electrophoresed lHindIII DNA fragments serve as size markers. The arrows
indicate the DNA fragments which defined the genetic rearrangement
generating the TRK oncogeneTRK oncogene in radiation-associated thyroid tumours 313
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obtained with these samples were compared: (1) with data obtained
by screening 32 malignant and benign ‘spontaneous’ thyroid
tumours (including four in vitro culture cell lines) and (2) with
data previously obtained (Challeton et al, 1995; Bounacer et al,
1997) after the study of 25 of the radiation-associated tumours,
looking for the presence of activated ras and Ret genes.
In our study, carried out using the RT-PCR and Southern blot tech-
niques, a similar frequency of NTRK1/TPM3 rearrangements was
observed in radiation-associated and ‘spontaneous’ samples (6%).
These data are similar to that recently published by Beimfohr et al
(1999) studying a series of 81 tumours of children from Belarus who
had been exposed to radiactive iodine after the Chernobyl reactor
accident. The NTRK1-activating rearrangement was also observed in
a lymph-node metastasis of one of the radiation-associated PTC
(sample JE3: patient JE). In contrast to RET, relatively few studies
have been devoted to NTRK1 activation in ‘spontaneous’ thyroid
tumours (Bongarzone et al, 1989; Greco et al, 1992, 1995; Wajjwalku
et al, 1992; Said et al, 1994; Butti et al, 1995; Delvincourt et al, 1996).
In this type of tumour, it has been shown that NTRK1 rearrangements
seem to be present exclusively in PTC with a frequency varying from
25% in Italian studies (Bongarzone et al, 1989; Greco et al, 1992;
Butti et al, 1995) to less than 5% in French and Japanese studies
(Wajjwalku et al, 1992; Said et al, 1994; Delvincourt et al, 1996). This
difference may be the consequence of geographical factors, as
suggested by Delvincourt et al (1996) studying a homogeneous popu-
lation from the Champagne-Ardennes region of France. However, the
possibility cannot be excluded that using the technique of transfection
of high molecular weight tumour DNA in 3T3 cells, as was the case in
the Italian studies, Delvincourt et al (1996) and Said et al (1994)
would have also found a higher frequency of activation and perhaps
new NTRK1 chimaeric genes.
Up to date, there is no report concerning NTRK1 activation in
radiation-associated thyroid tumours. In our present study, the
overall frequency of NTRK1 rearrangements considering only the
radiation-associated and ‘spontaneous’ PTC, is 14% (2/14) and
12% (2/17) respectively. In contrast with results previously
reported by us concerning the RET/PTC oncogene (Bounacer et al,
1997), all the radiation-associated follicular adenomas were nega-
tive for the presence of NTRK1 activating rearrangements, in
agreement with previous and present data concerning ‘sponta-
neous’ thyroid follicular adenomas (Wajjwalku et al, 1992; Said et
al, 1994; Delvincourt et al, 1996).
The type of activating rearrangement of the NTRK1 proto-
oncogene observed by us in our radiation-associated and ‘sponta-
neous’ thyroid tumours, involved exclusively the TPM3 gene.
Little is known about the mechanism by which the NTRK1 proto-
oncogene is damaged by genotoxic agents, to generate a
chimaeric gene. Until present, the only study carried out to char-
acterize the sequence of the genomic regions involved in the
NTRK1 activating rearrangements, has been done by Butti et al
(1995) in three ‘spontaneous’ PTC and concerns exclusively the
TRK oncogene (TPM3-NTRK1). These authors showed that the
different breakpoints occurred in intronic regions of both genes.
They identified in these regions the presence of some recombino-
genic elements including palindromes, direct and inverted repeats
and Alu sequences. However, the significance of these results in
the process of rearrangement after irradiation is still unknown,
because there are no similar studies concerning thyroid radiation-
associated tumours. Whether or not the mechanism of rearrange-
ment is the same in ‘spontaneous’ and radiation-associated
tumours, will probably be elucidated studying the breakpoints in
both types of tumours.
Twenty-five of our radiation-associated tumours were previously
screened for the presence of ras mutations and RET/PTC rearrange-
ments (Challeton et al, 1995; Bounacer et al, 1997) (Table 1). The
overall frequencies of ras, RET and NTRK1 alterations in these
radiation associated tumours are 12%, 60% and 8% respectively.
This result confirms, as previously reported by us for tumours orig-
inated after therapeutic radiation (Bounacer et al, 1997) and by
others in tumours appearing after the Chernobyl fallout (Ito et al,
1994; Fugazzola et al, 1995; Klugbauer et al, 1995; Nikiforov et al,
1997), that RET oncogenic activation by rearrangement represents
the major genetic lesion associated with radiation-induced thyroid
tumorigenesis. Three of the radiation-associated tumours presented
simultaneously two different genetic alterations: in two cases a
RET/PTC1 rearrangement and a Ha-ras mutation (patients PE1 and
PL17) and in one case a RET/PTC1 and a TRK rearrangement
(patient JE2) (Table 1). It is tempting to speculate about an eventual
mechanism of cooperation between the simultaneously altered ras
and  RET genes in the initiation or progression of our human
radiation-associated tumours, as previously described by Santoro et
al (1993) studying an in vitro culture rat thyroid epithelial cell line.
The fact that only a low number of our positive radiation-associated
tumours present two simultaneous genetic alterations (3/25), pleads
in favour of an alternative role of the ras, RET and NTRK1 genes in
the induction of the tumorigenic process. However, an eventual
cooperation between these genes and/or with other unknown genes
must not be neglected.
In conclusion, taken together our data: (a) show that the NTRK1
proto-oncogene is activated by rearrangement with a similar
frequency in ‘spontaneous’ and radiation-associated thyroid
tumours; (b) show that the NTRK1 proto-oncogene activating
rearrangements play a role in the development of a minority of radi-
ation-associated PTC but not in adenomas and (c) confirm that RET
oncogenic activation by rearrangement is the major genetic event
associated with ionizing radiation-induced thyroid tumorigenesis.
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